Please use this identifier to cite or link to this item: http://repository.kln.ac.lk/handle/123456789/17835
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSiriwardana, R.C.en_US
dc.contributor.authorNiriella, M.A.en_US
dc.contributor.authorDassanayake, A.S.en_US
dc.contributor.authorde Silva, A.P.en_US
dc.contributor.authorGunetilleke, B.en_US
dc.contributor.authorde Silva, H.J.en_US
dc.date.accessioned2017-10-16T10:20:29Zen_US
dc.date.available2017-10-16T10:20:29Zen_US
dc.date.issued2016en_US
dc.identifier.citationSri Lanka Medical Association, 129th Anniversary International Medical Congress. 2016: 221en_US
dc.identifier.issn0009-0895en_US
dc.identifier.urihttp://repository.kln.ac.lk/handle/123456789/17835en_US
dc.descriptionPoster Presentation Abstract (PP 122), 129th Anniversary International Medical Congress, Sri Lanka Medical Association, 25-27 July 2016 Colombo, Sri Lankaen_US
dc.description.abstractINTRODUCTION: Alpha-fetoprotein (AFP) is a biomarker for hepatocellular carcinoma (HCC). The significance of pre-treatment AFP (pt-AFP) in non-viral HCC (nvHCC) is not clear. METHOD: Patients with nvHCC, referred to a Hepatobiliary Clinic from September 2011-2015 were screened. Clinical evaluation, liver biochemistry, pt-AFP and contrast enhanced CT abdomen were performed. HCC was diagnosed using American Association for the Study of Liver Disease guidelines and TNM staged. nvHCC was diagnosed in HCC, negative for HBsAg and anti-HCVAb. Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores were calculated. All values are presented as median (range). Differences between groups were tested using Pearson’s Chi-square, Mann Whitney U and Kruskal-Wallis tests. Cumulative survival and recurrence rates were calculated by the Kaplan-Meier method. Difference between survival was evaluated by the log-rank test. A p<0.05 was considered significant. RESULTS: Three hundred and eighty nine patients with nvHCC [age 64 (12-88) years; 344 (88.4%) males] were screened. Two hundred and thirty three (59.9%) had diabetes; 187 (48.1%) were regular, 79 (20.3%) social, 123 (31.6%) non-consumers of alcohol]. Three hundred and twenty nine (84.6%) had cirrhosis [Child A (57.3%), B (32.4%), C (10.3%); median CTP 6 (1-14), MELD 11(5-28)]. One hundred and seventy seven (45.5%) HCCs were TNM stage 3, with median diameter 6cm (0.9-26.5). Two hundred and thirty three (59.9%) had no vascular or visceral invasion. Median AFP was 25.46ng/ml (1.16-100,000) [AFP<10ng/ml: n=160(41.2%), AFP>400ng/ml: n=89(22.9%)]. Females (p<0.05), vascular invasion (p<0.001), diameter>5cm (p<0.05), late TNM stage (p<0.001) and non-surgical candidates had higher AFP levels. Diffuse (p<0.001), invasive (p<0.001) and late stage tumours (p<0.001) had AFP>400ng/ml. AFP<400ng/ml was associated with longer survival compared to AFP>400ng/ml (16 vs. 7 months, p<0.001). CONCLUSIONS: Although pt-AFP was not helpful for diagnosis of nvHCC, AFP>400ng/ml was associated with aggressive tumour behaviour and poor prognosis.en_US
dc.language.isoen_USen_US
dc.publisherSri Lanka Medical Associationen_US
dc.subjectCarcinoma, Hepatocellularen_US
dc.subjectCarcinoma, Hepatocellular-etiologyen_US
dc.subjectalpha-Fetoproteinsen_US
dc.subjectalpha-Fetoproteins-therapeutic useen_US
dc.titleSignificance of pre-treatment serum alpha-fetoprotein in hepatocellular carcinoma of non-viral aetiologyen_US
dc.typeConference Abstracten_US
Appears in Collections:Conference Papers

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.